Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2016
Source ID
10.1016/j.bbmt.2016.07.007

Entities

People

  • Amer Beitinjaneh
  • Amrita Krishnan
  • Anita D'Souza
  • Baldeep Wirk
  • Bipin N Savani
  • Cindy J. Lee
  • Cristina Gasparetto
  • Dan Vogl
  • David Vesole
  • Emma C. Scott
  • Gerhard C Hildebrandt
  • Henry Fung
  • Hillard M Lazarus
  • Jason Tay
  • Jean Yared
  • Jennifer Le-Rademacher
  • Jiaxing Huang
  • Joseph Mikhael
  • Kenneth Meehan
  • Leona Holmberg
  • Manish Sharma
  • Matt Kalaycio
  • Muneer H Abidi
  • Muthalagu Ramanathan
  • Parameswaran Hari
  • Richard T. Maziarz
  • Robert Kyle
  • Saad Usmani
  • Shaji K Kumar
  • Siddhartha Ganguly
  • Taiga Nishihori
  • Tomer Mark
  • Yago Nieto

Organizations

  • Alexion Pharmaceuticals
  • Amgen
  • Bristol-Myers Squibb
  • Celgene
  • Chiron Corporation
  • Elevance Health, Inc.
  • Fred Hutchinson Cancer Center
  • Genzyme
  • Gilead Sciences
  • Health Research
  • Health Resources and Services Administration
  • Incyte
  • Jazz Pharmaceuticals
  • Leukemia & Lymphoma Society
  • Medical College of Wisconsin
  • Miltenyi Biotec
  • National Marrow Donor Program
  • Office of Naval Research
  • Onyx Pharmaceuticals
  • Otsuka (United States)
  • Otsuka Pharmaceutical
  • Pharmacyclics
  • Roche (United States)
  • Roswell Park Comprehensive Cancer Center
  • Sanofi-Aventis
  • Seagen
  • Sigma-Tau Pharmaceuticals (United States)
  • Spectrum Pharmaceuticals
  • St. Baldrick's Foundation
  • Swedish Orphan Biovitrum
  • Takeda Oncology
  • United States Public Health Service
  • University of Minnesota

Tags

Technology Areas

  • Biotechnology